H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Biohaven (BHVN) to $30 from $54 and keeps a Buy rating on the shares. The firm says the Oberland Capital debt facility covers only part of the expenses related to troriluzole and the company’s research and development programs, likely necessitating dilutive equity capital.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- 3 Best Stocks to Buy Now, 8/12/2025, According to Top Analysts
- Promising Developments and Regulatory Progress at Biohaven Ltd. Support Buy Rating
- Biohaven’s Strategic Advances and Promising Data Drive Buy Rating
- Biohaven reports Q2 non-GAAP EPS ($1.63), consensus ($1.57)
- BHVN Earnings this Week: How Will it Perform?